CTOs on the Move

ColoWrap

www.colowrap.com

 
ColoWrap is the first clinical colonoscopy compression device that prevents the need for manual abdominal pressure and patient repositioning during colonoscopy.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.colowrap.com
  • 413, W Cornwallis Rd
    Durham, NC USA 27707
  • Phone: 919.451.1803

Executives

Name Title Contact Details

Similar Companies

Aeroflow Healthcare

Live Better Today! Durable medical equipment covered by insurance delivered to your door!

RxNT

RxNT is a Annapolis, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TMS International

TMSi is specialized in developing of high-quality measurement systems for electrophysiological parameters such as EEG and High Density EMG. Our systems are highly versatile and have the best data quality possible.

Aspen Pharmacare Canada

We have a proud heritage dating back more than 160 years and is committed to sustaining life and promoting healthcare through increasing access to our high quality, affordable medicines and products. As a leading global player in specialty, branded and generic pharmaceuticals, we have an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. We continue to increase the number of lives benefiting from our products that reach more than 150 countries. In line with the our commercial, production and territorial strategies, we have identified Thrombosis, Anaesthetics, High Potency & Cytotoxics as our focused therapeutic categories that will receive our highest focus based on materiality and future potential.

Amolyt Pharma

Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.